Cannabis Law Report
JULY 31, 2019
billion by 2025, according to a new report by Grand View Research, Inc., The market is primarily driven by the ongoing legalization of medical marijuana for treating patients with Parkinson’s disease, cancer, arthritis, Alzheimer’s disease, neurologic problems such as depression, anxiety, & epilepsy, and others.
Otherside Farms
NOVEMBER 13, 2019
In actuality, experts project that the industry will be worth sixteen billion dollars by the end of 2025. The product, although distasteful to the average Joe, might be a bar of candy for HIV/AIDS and cancer patients. CBD can calm epilepsy. It is because. Cannabidiol Boosts Your Appetite. Recall, cancer causes appetite loss.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 12, 2020
It has approved use of cannabis extracts for treatment of a range of illnesses and conditions, including cancer, epilepsy, Alzheimer’s, Parkinson’s disease and anxiety. The Government has promised to open more clinics in greater Bangkok, with patients able to book appointments via a specialised smartphone app.
Cannabis Law Report
FEBRUARY 18, 2020
Researchers predict that the market will be valued at $7 billion by the year 2025. And according to a Nielsen analytical report , the US market of legal marijuana will reach $41 billion in revenue by 2025, meaning that New York will make up close to 17% of the market share. patient application. billion in revenue.
Cannabis Law Report
JULY 26, 2019
The medicinal cannabis is believed to possess traits that cure critical ailments like Cancer, AIDS, cancer, PTSD, depression, epilepsy and seizures. The Australian cannabis market is expected to have a net worth of approximately $55 million by the end of 2025. But the health sector was the most impacted, and positively.
Cannabis Law Report
JANUARY 5, 2022
This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
Cannabis Law Report
NOVEMBER 16, 2021
The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. The market for treating aging disorders and extending healthy lifespan is expected to be at least $600 billion by 2025 1 according to a major investment bank.
Expert insights. Personalized for you.
40 
Let's personalize your content